Evidence map›Paper›PMID 31250045›Full record

Trial reportEuropean journal of clinical pharmacology2019

Influence of the aldehyde dehydrogenase 2 polymorphism on the vasodilatory effect of nitroglycerin in infants with congenital heart disease and pulmonary arterial hypertension.

Tatsuya Nagano, Kentaro Ushijima, Naoyuki Taga, Mamoru Takeuchi, Masa-Aki Kawada, Kenichi Aizawa, Yasushi Imai, Akio Fujimura

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Tatsuya NaganoDivision of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, 329-0498, Japan.
Kentaro UshijimaDivision of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, 329-0498, Japan.
Naoyuki TagaDepartment of Anesthesiology and Critical Care Medicine, Jichi Medical University, Tochigi, Japan.
Mamoru TakeuchiDepartment of Anesthesiology and Critical Care Medicine, Jichi Medical University, Tochigi, Japan.
Masa-Aki KawadaDivision of Pediatric and Congenital Cardiovascular Surgery, Jichi Children's Medical Center Tochigi, Jichi Medical University, Tochigi, Japan.
Kenichi AizawaDivision of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, 329-0498, Japan.
Yasushi ImaiDivision of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, 329-0498, Japan.
Akio FujimuraDivision of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, 329-0498, Japan. akiofuji@jichi.ac.jp.ORCID http://orcid.org/0000-0002-5160-5777
Jichi Medical University · JP

Funding

Japan Research Foundation for Clinical Pharmacology none
6 · The paper itself

Abstract

purposeThe influence of the aldehyde dehydrogenase 2 (ALDH2) gene polymorphism on the pharmacokinetics and haemodynamics of nitroglycerin (GTN) was determined in human subjects.

methodsEighteen infants (nine each with and without ALDH2 gene polymorphism) with congenital heart disease and pulmonary arterial hypertension participated in this study. GTN treatment started at a dose of 2 μg/kg/min, and the dose was escalated by 1-2 μg/kg/min until pulmonary vascular resistance (PVR) was reduced by more than 30%. The plasma GTN concentration and PVR were measured at the end of each infusion period.

resultsPlasma GTN concentrations were significantly higher in patients with the ALDH2 gene polymorphism than in those without the polymorphism. Conversely, the reduction in PVR was smaller in patients with the ALDH2 gene polymorphism than in those without.

conclusionsThese data suggest that the ALDH2 gene polymorphism influences the pharmacokinetics and haemodynamics of GTN in human subjects.

Indexed as

Aldehyde Dehydrogenase, MitochondrialFemaleGenotypeHeart DiseasesHumansInfantMaleNitroglycerinPolymorphism, GeneticPulmonary Arterial HypertensionVasodilationVasodilator AgentsAldehyde Dehydrogenase, MitochondrialALDH2 protein, humanNitroglycerinVasodilator AgentsALDH2 polymorphismCongenital heart diseaseNitroglycerinPulmonary hypertension

Identifiers

PMID31250045
OpenAlexW2954096533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.